Group 1 - The 2025 World Dental Congress, hosted by the FDI, took place in Shanghai from September 9 to 12, attracting over 30,000 experts and industry representatives from more than 100 countries, marking its return to China after 19 years [1] - Boren Dental showcased multiple new products and four major solutions at the event, highlighting its strong brand presence and innovative technologies, which garnered significant attention from industry peers [1] - Boren Group focuses on providing digital and intelligent overall solutions for dental medical institutions, aiming to achieve resource sharing and collaborative development through a smart platform [1] Group 2 - The new mobile CBCT from Boren Dental attracted many attendees due to its convenience, addressing pain points faced by private dental institutions, such as high equipment costs and long payback periods [1] - The mobile CT represents a new model of mobile diagnosis, allowing high-quality dental imaging services to reach communities, towns, schools, and nursing homes, thus facilitating early detection and treatment for patients [3] - Boren Dental's philosophy of empowering dentists and making dental care accessible is embodied in the development of the mobile CBCT, which serves as a breakthrough for private dental institutions in a competitive market [3]

Core Viewpoint - The company has experienced a significant decline in revenue and net profit due to various macroeconomic factors and policy changes in the healthcare sector, leading to increased pressure on its financial performance [1][2]. Financial Performance - In 2024, the company reported an operating revenue of 8.312 billion yuan, a decrease of 9.13% year-on-year [1]. - The net profit attributable to shareholders was 55.2806 million yuan, down 79.77% compared to the previous year [1]. - By the end of 2024, the company's accounts receivable balance was approximately 5.2 billion yuan, accounting for 36% of total assets [2]. Cost Structure - Despite a decline in revenue, the company’s sales, management, and financial expenses did not decrease proportionately, with reductions of 6.05% and 8.53% respectively, which were smaller than the revenue decline [2]. - The company faced increased pressure on cash flow due to extended accounts receivable collection periods and shorter accounts payable turnover days [2]. Market Challenges - The company has been affected by national policies and macroeconomic conditions, leading to a downward trend in revenue over the past two years [2]. - In Q1 2025, the company reported its first quarterly loss since listing, with revenues of 1.662 billion yuan and a net profit of -69.2587 million yuan, alongside a gross margin decline to 20.78% [2]. Strategic Initiatives - To counteract the decline in traditional business profits, the company aims to explore new growth areas by integrating artificial intelligence (AI) technology into medical applications [3]. - The company plans to collaborate with various stakeholders in the healthcare industry to develop and implement AI solutions across multiple healthcare scenarios, including diagnosis, patient management, and smart testing [3]. - The company has not disclosed specific R&D investment figures for its AI initiatives but emphasizes its strong capabilities in medical data governance and AI application development [3].